T1	Participants 715 791	252 of the 331 patients were evaluable by GPA. Of those, 211 had lung cancer
T2	Participants 793 829	Breast cancer patients were excluded
T3	Participants 139 231	patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA)
